首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Comment on Gomez et. al. Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’

【2h】

Comment on Gomez et. al. Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’

机译：评论Gomez等。等回应Wasserman等人的文章。等（2018）与在墨西哥更换10价疫苗相比对13价肺炎球菌结合疫苗的持续使用进行建模。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional information and clarifies potential misinterpretations.

机译：在最近的一封信中，Gomez等人。等在墨西哥对从13价（PCV13）转换为10价（PCV10）肺炎球菌结合疫苗的临床和经济影响进行评估时，对我们的原始分析提出了批评。此评论针对Gomez等。等人的评论，以及其他信息，并澄清了可能的误解。

著录项

期刊名称 Human Vaccines Immunotherapeutics
作者
Matt Wasserman; Maria Gabriela Palacios; Ana Gabriela Grajales; Michele Wilson; Cheryl McDade; Raymond Farkouh;
展开▼
作者单位

展开▼
年(卷),期 2019(15),3
年度 2019
页码 -1
总页数 3
原文格式 PDF
正文语种
中图分类免疫学;
关键词
Economic Evaluation; Pneumococcal Conjugate Vaccine; Cost-effectiveness;

机译：经济评价;肺炎球菌结合疫苗;成本效益;
入库时间 2022-08-21 11:39:42

相似文献

外文文献
中文文献
专利

1. Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'" [J] . Wasserman Matt, Gabriela Palacios Maria, Gabriela Grajales Ana, Human vaccines & immunotherapeutics. . 2019,第3期

机译：评论Gomez等。 al。 “由Wasserman等响应文章。（2018）'建模13价肺炎球菌缀合物疫苗的持续使用与切换到墨西哥的10价疫苗相比'”
2. Response to article by Matthew Wasserman et al. (2018): "Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico" [J] . Gomez Jorge A., Guzman Holst Adriana, Nieto Javier Human vaccines & immunotherapeutics. . 2019,第3期

机译：Matthew Wasserman等人的回应。（2018）：“与墨西哥的10价疫苗相比，建模13价肺炎球菌共轭疫苗的持续使用”
3. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico [J] . Wasserman Matthew, Gabriela Palacios Maria, Gabriela Grajales Ana, Human vaccines & immunotherapeutics. . 2019,第3期

机译：与切换到墨西哥的10价疫苗相比，建模13价肺炎球菌共轭疫苗的持续使用
4. Response to article by Matthew Wasserman et al. (2018): Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico [O] . Jorge A. Gómez, Adriana Guzman Holst, Javier Nieto 2019

机译：对Matthew Wasserman等人的文章的回应。（2018）：与在墨西哥使用10价疫苗相比对13价肺炎球菌结合疫苗的持续使用进行建模
5. Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico” [O] . Jorge A. Gómez, Adriana Guzman Holst, Javier Nieto 2018

机译：Matthew Wasserman等人的回应。（2018）：“与墨西哥的10价疫苗改造了13价肺炎球菌缀合物疫苗的持续使用”

Comment on Gomez et. al. Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’

摘要

著录项

相似文献

相关主题

期刊订阅